Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease.
Alkhouri
Naim
N
Hupertz
Vera
V
Mahajan
Lori
L
D000068879:Adalimumab; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003125:Colostomy / Q000009:adverse effects*; D003424:Crohn Disease / Q000150:complications*; D005260:Female; D006801:Humans; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab